BRCA2 affects the efficiency of DNA double-strand break repair in response to N-nitroso compounds with differing carcinogenic potentials

WEN-TING ZHAO¹, YU-TIAN WANG², ZHAO-WEI HUANG² and JING FANG¹

¹Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, SIBS, Chinese Academy of Sciences, Shanghai 200031; ²Department of Gastroenterology, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, P.R. China

Received December 6, 2012; Accepted March 5, 2013

DOI: 10.3892/ol.2013.1269

Abstract. The tumor suppressor gene breast cancer susceptibility gene 2 (BRCA2) is frequently mutated or epigenetically repressed in human cancer and has a significant role in the homologous recombination (HR) of DNA double-strand breaks (DSBs). Although N-nitrosodiethylamine (NDEA), N-nitrosodiethanolamine (NDELA) and N-nitrosodipropylamine (NDPA) have similar chemical structures and are able to induce DNA damage, they have varying carcinogenic risks. We hypothesized that the DNA damage repair pathways that are induced by these N-nitroso compounds (NOCs) may differ and that this may contribute to the genotoxic-carcinogenic effect of the NOCs. The present study aimed to characterize the formation of DSBs by NDEA, NDELA and NDPA and also to investigate whether BRCA2 is involved in the DNA damage response. The NOCs were observed to time-dependently induce DSBs and the expression of γ-H2AX in gastric cancer SGC7901 cells. It was observed that the DNA damage induced by NDEA, the most potent carcinogen, was not repaired as efficiently as that caused by NDELA or NDPA. The expression of BRCA2 and RAD51 was demonstrated to be inhibited by NDEA treatment but upregulated by NDELA or NDPA treatment. Furthermore, the knock down of BRCA2 expression impaired the DNA damage repair induced by NDELA or NDPA. The cells with this knock down exhibited an increased sensitivity to NDELA or NDPA treatment, but not to NDEA. These findings suggest that a BRCA2-mediated pathway contributes to differential DSB repair and sensitivity in response to NOC exposure and that it may be associated with the genotoxic-carcinogenic potential of NOCs.

Introduction

Tumor suppressor breast cancer susceptibility gene 2 (BRCA2) is responsible for a large percentage of familial breast cancer cases (1,2). In addition to breast cancer, BRCA2 mutations are also linked to other types of cancer, including ovarian, hepatocellular, pancreatic, prostate and gastric tumors (3-5). The protein encoded by this gene is involved in the repair of chromosomal damage and has an essential role in the repair of DNA double-strand breaks (DSBs) through homologous recombination (HR) (6-8). In support of this theory, mammalian cells lacking functional BRCA2 have been shown to be sensitive to DNA damaging agents (9,10), exhibit genomic instability (11-13) and are deficient in homology-directed DNA repair (8,14).

BRCA2 interacts with a number of DNA repair proteins, including γ-H2AX and RAD51 (15-17). γ-H2AX foci formation functions to recruit DNA repair factors to the damaged sites, enforcing the HR of DNA DSBs and linking the process of chromatin remodeling to DNA repair (16,18,19). RAD51 is a DNA recombinase that is essential in initiating the HR process by mediating DNA strand exchange during recombination. BRCA2 is required for RAD51 foci assembly in response to ionizing radiation (IR)-induced DNA DSBs (15,17,20,21).

N-nitroso compounds (NOCs) and their precursors exist extensively in the environment, certain occupational settings, diets, tobacco products, cosmetics and pharmaceutical products, and are endogenously formed in the human body from dietary components (22,23). Many NOCs have been identified as carcinogenic (23-27) and the International Agency for Research on Cancer (IARC) has classified four NOCs as probably carcinogenic to humans and another 15 as possibly carcinogenic (23,28-30). The carcinogenic effect of NOCs

Correspondence to: Professor Yu-Tian Wang, Department of Gastroenterology, Changzheng Hospital, The Second Military Medical University, No. 415 Fengyang Road, Shanghai 200031, P.R. China
Email: yutianwangcn@yeah.net

Professor Jing Fang, Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, SIBS, Chinese Academy of Sciences, No. 294 Taiyuan Road, Shanghai 200003, P.R. China
Email: fangj586@126.com

Key words: DNA double strand breaks, BRCA2, N-nitroso compounds, DNA damage repair
is usually attributed to their DNA damaging and genotoxic properties (23,31,32).

Certain studies have shown that NOCs can be induced to induce DNA single-strand breaks and DSBs (31,32), suggesting that DNA repair by the HR pathway may function in repairing the DNA damage induced by NOCs. However, there have been no studies on the role of HR in the repair of DNA damage induced by NOCs. We hypothesized that, as a DNA damage response, the BRCA2-mediated HR pathway may be involved in DNA damage repair induced by NOCs and that this may contribute to their carcinogenic effect. Three NOCs, N-nitrosodiethylamine (NDEA), N-nitrosodietanolamine (NDELA) and N-nitrosodipropylamine (NDPA), with similar chemical structures and varying carcinogenic risks, which were classified into differing carcinogenic classes in humans according to the IARC, were investigated in the present study (23,24,28-30). The aim of the present study was to characterize the formation and repair of the DNA damage induced by NOCs. We hypothesized that, as a DNA damage response, the BRCA2-mediated HR pathway may be involved in the DNA damage response to these NOCs.

Materials and methods

Cells and reagents. Epidemiological studies indicate that NOCs are positively associated with stomach cancer, therefore, the human gastric cancer SGC7901 cell line was used in the present study. The SGC7901 cell line was established from an untreated patient with progressive adenocarcinoma of the stomach. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum. The SGC7901 cells stably transfected with the vector and BRCA2 siRNA (siBRCA2) were cultured in DMEM containing 200 µg/ml of G418 (Invitrogen, Carlsbad, CA, USA). The NDEA, NDELA, NDPA and dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis, MO, USA). All chemicals and solvents were of the highest grade commercially available. The NOCs were dissolved in sterile DMSO (0.1%) and freshly prepared each time prior to use. Logarithmically growing SGC7901 cells were treated with NOCs at appropriate concentrations where indicated.

Comet assay. The comet assay (Trevigen, Inc., Gaithersburg, MD, USA) was performed as described previously, using neutral conditions to detect the DSBs (33). In brief, the cells were harvested, washed with ice-cold PBS and combined with molten LMP agarose, then 75 µl (500-1,000 cells) was immediately added to the comet slide. Subsequent to being hardened, the slides were incubated for 30 min in lysis solution at 4°C, then rinsed with 1X Tris/borate/EDTA prior to electrophoresis for 60 min at 30 V. The slides were rinsed with distilled H2O, placed in 70% ethanol for 10 min and then air-dried. To visualize the DNA, 50 µl of a 1:1,000 dilution of SYBR Green (Molecular Probes, Invitrogen) in PBS was added to each slide. The slides were visualized using fluorescence microscopy (Leica DMS 4000B; Leica, Mannheim, Germany). The comet tail to head ratios or tail lengths were determined using the software package ‘Comet Assay II’ (Perceptive Instruments, Haverhill, Suffolk, UK). A minimum of 50 cells per experiment were analyzed. All the experiments were performed at least three times independently and in triplicate.

Western blotting. The cells were harvested and lysed with a lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 100 µg/ml phenylmethylsulfonyl fluoride and 1% Triton X-100 for 30 min on ice. Total cellular extracts (50 µg) were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were probed with specific primary antibodies, followed by incubation with IRDye680-conjugated secondary antibodies (Rockland, Inc., Gilbertsville, PA, USA). Detection was performed using an Odyssey IR imaging system (LI-COR Biotechnology, Lincoln, NE, USA). The following antibodies were used for the immunoblotting studies: mouse anti-γ-H2AX (serine 139; Upstate, Charlotteville, VA, USA), mouse anti-BRCA2 (Cell Signaling Technology, Beverly, MA, USA), rabbit polyclonal anti-RAD51 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and anti-β-actin (Sigma).

Immunofluorescence studies. The cells were plated onto coverslips and treated with 1X IC50 concentrations of NDEA, NDELA and NDPA (0.76, 1.09 and 0.39 mM, respectively) for 1 h. The cells were then fixed and stained with monoclonal anti-γ-H2AX (Upstate). Subsequent to being stained with Alexa Fluor 488-conjugated goat anti-mouse secondary antibodies (Invitrogen), the slides were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA) containing 5 ng/ml 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories). The staining images were captured using fluorescence microscopy (Leica DMS 4000B) and a Spot digital camera (Spot Imaging Solutions, Sterling Heights, MI, USA).

Clonogenic survival assay. To determine the cytotoxicity and IC50 concentrations of NDEA, NDELA and NDPA, a clonogenic survival assay was performed on 60-mm cell culture dishes as described previously (34). The SGC-7901 cells were treated with various concentrations of NDEA, NDELA or NDPA for 1 h, followed by drug-free incubation for 10 days. The colonies were stained with crystal violet and counted if ≥50 cells were present. The IC50 concentration was calculated as the concentration of NDEA, NDELA or NDPA that killed 50% of the untreated control colonies.

Small interfering RNA (siRNA) transfection assays. BRCA2 siRNA (SiBRCA2) oligos containing the target sequences of 5′-AAGACACGCTGCAACAAAGCA-3′ were designed and synthesized. Following annealing, the double-stranded siBRCA2 fragment was inserted into a pSilencer 2.1-U6-neo vector (Ambion, Austin, TX, USA) and transfected into the SGC7901 cells with Lipofectamine-2000 (Invitrogen). The pSilencer 2.1-U6-neo vector containing a scrambled sequence (Ambion) was transfected as a nonspecific control. Stable cell lines were established by performing selection in a medium containing G418.

Statistical analyses. Images of 50 randomly selected cells were evaluated per treatment and the test was performed three times. The Student's t-test was used to provide the statistical
comparisons and P<0.05 was considered to indicate a statistically significant difference.

**Results**

*NDEA, NDELA and NDPA-induced DNA DSBs*. First, the effects of NDEA, NDELA and NDPA on the DNA damage in the SGC7901 cells were examined. DNA damage was evaluated using the comet assay under neutral electrophoresis conditions to predominantly detect the DSBs. Logarithmically growing SGC-7901 cells were treated with 1X IC_{50} concentrations of NDEA (0.76 mM), NDELA (1.09 mM) or NDPA (0.39 mM) for 15, 30 and 60 min. The comet assays revealed that NDEA, NDELA and NDPA induced apparent DNA damage.
damage in the SGC7901 cells as evidenced by the presence of DNA comet tails (Fig. 1A). Analysis of the tail to head ratio, which reflected the degree of DNA damage in the cells, showed that each of the three compounds induced a time-dependent increase in the extent of DNA damage (Fig. 1B).

Differential efficiency of DNA damage repair in response to NDEA, NDELA and NDPA treatment. The comet assay and the data on the expression of γ-H2AX demonstrated that the three compounds, NDEA, NDELA and NDPA, were able to induce a time-dependent increase in the extent of DNA damage. These observations indicated that these three NOCs similarly induced the generation of DSBs. As with the varying carcinogenic potentials, it was unclear whether these NOCs induced similar DNA repair. We hypothesized that the repair mechanism of these NOC-induced DSBs may be different. To examine this hypothesis, the SGC7901 cells were treated with 1X IC₅₀ concentrations of NDEA (0.76 mM), NDELA (1.09 mM) or NDPA (0.39 mM) for 1 h, followed by a 12-h drug-free incubation to allow DNA repair. The formation and resolution of the DNA damage were then analyzed using the comet assay. Following a drug-free incubation of 12 h, the tail to head ratio of the comet DNA in the cells treated with NDELA (P<0.05) or NDPA (P<0.01) was observed to be significantly reduced (Fig. 2A and B). However, there was no apparent reduction in the tail to head ratio of the comet DNA in the cells treated with NDEA (P>0.05). The levels of γ-H2AX expression were also studied and it was observed that following a drug-free incubation of 12 h, there was a significant reduction in the expression of γ-H2AX in the SGC7901 cells treated with NDELA or NDPA (Fig. 2C). However, there was no clear change in the γ-H2AX levels in the cells treated with NDEA. These observations suggested that the DSBs induced by NDELA or NDPA were more effectively repaired than those induced by NDEA.

BRCA2-mediated HR contributes to the differential repair of NOC-induced DSBs in SGC7901 cells. In order to determine whether HR was involved in the repair of NOC-induced DSBs, the expression levels of BRCA2 and RAD51, two key proteins in HR (4,8,20), were observed in response to the NOC treatment. The SGC7901 cells were treated with 1X IC₅₀ concentrations of NDEA, NDELA and NDPA for 15 and 60 min. The expression of BRCA2 and RAD51 was reduced in the SGC7901 cells treated with NDEA (Fig. 3A). However, the expression levels of BRCA2 and RAD51 were notably upregulated in a time-dependent manner in the cells treated with NDELA or NDPA (Fig. 3A). The results suggest that the BRCA2-RAD51-mediated HR pathway may be...
The role of BRCA2 in the repair of NOC-induced DNA damage was further investigated. A BRCA2-targeted siRNA was designed (as described in the Materials and methods) and stably transfected into the SGC7901 cells. The effectiveness of the siBRCA2 construct in knocking down the endogenous BRCA2 level was demonstrated by western blotting. As shown in Fig. 3B, the expression of BRCA2 was effectively knocked down using BRCA2 siRNA transfected into the SGC7901 cells. The control group consisted of SGC7901 cells stably transfected with the control vector plasmid. The vector- and siBRCA2-transfected SGC7901 cells were treated with 1X IC50 concentrations of NDEA, NDELA, or NDPA for 1 h, followed by a 12-h drug-free incubation. Similar to the cells treated with NDEA, the level of γ-H2AX expression in the vector cells was reduced following the drug-free incubation. The DNA damage induced by NDELA or NDPA was not repaired as effectively as in the vector cells. DMSO (1 mM) treatment was used as a negative control. BRCA2, breast cancer susceptibility gene 2; NOC, N-nitroso compound; NDEA, N-nitrosodiethylamine; NDELA, N-nitrosodiethanolamine; NDPA, N-nitrosodipropylamine; siRNA, small interfering RNA.
BRCA2-knockdown cells treated with NDELA (Fig. 3D) or NDPA (Fig. 3E) was not reduced to the level of the vector cells following the drug-free incubation. The results showed that in the BRCA2-knockdown cells, the DNA damage induced by NDELA or NDPA was not repaired as effectively as in the vector cells. This also suggested that BRCA2 contributes to the variations in DNA repair in response to these NOC-induced DSBs.

**BRCA2 confers sensitivity to NOC treatment.** Based on the previous observations that BRCA2 is significant for the repair of DNA damage induced by NOCs, we hypothesized that BRCA2 may affect the sensitivity to NOCs. To determine whether BRCA2 affects the sensitivity to NDEA, NDELA and NDPA, a clonogenic survival assay was performed. The vector- and siBRCA2-transfected SGC7901 cells were treated with various concentrations of NDEA, NDELA or NDPA for 1 h, followed by drug-free incubations. When the IC_{50} concentrations were compared, the results showed that the cells with the endogenous knock down of BRCA2, caused by RNA interference, exhibited a 2-2-fold increase in sensitivity to NDEA (Fig. 4B) or NDPA (Fig. 4C) compared with the vector cells. No significant change was observed in the sensitivity to NDEA (Fig. 4A). These results show that BRCA2 confers sensitivity to NOCs.

**Discussion**

NOCs are widely distributed in the environment and are recognized as genotoxic agents and possible chemical carcinogens. Their carcinogenicity mainly depends on their genotoxicity (23-27). NDEA, NDELA and NDPA belong to carcinogen groups 2A, 2B and 3, respectively (28-30). In the present study, it was observed that these three NOCs were able to similarly induce time-dependent DSBs in the SGC7901 cells with the endogenous knock down of BRCA2, caused by RNA interference, exhibited a 2-2-fold increase in sensitivity to NDEA (Fig. 4B) or NDPA (Fig. 4C) compared with the vector cells. No significant change was observed in the sensitivity to NDEA (Fig. 4A). These results show that BRCA2 confers sensitivity to NOCs.

DNA DSBs are the most lethal DNA lesions, posing an almost insurmountable challenge to the cells' DNA repair machinery. HR is a DSB repair pathway. The HR pathway uses one sister DNA strand as the repair template and repairs DNA DSBs with high fidelity (11,14,37). In order to understand why the repair of NOC-induced DSBs varied and to determine the role of HR in this process, the expression levels of BRCA2, RAD51, but NDEA did not. Furthermore, it was observed that the knock down of BRCA2 blocked NDELA- or NDPA-induced DNA damage repair and also that cells with this knock down showed an increased sensitivity to NDELA or NDPA. Taken together, these observations suggest that the BRCA2-mediated DNA repair pathway may have a significant role in NOC-induced DNA damage repair and that this may be associated with the differential carcinogenicity of these NOCs.

**Acknowledgements**

The present study was supported by grants from the Natural Science Foundation of China (Grant No. 81170385), the Shanghai Pujiang Talent Plan (07pyj4003), the Chinese Ministry of Science and Technology (2007BAC27B02) and the Chinese Academy of Sciences (KSCX2-YW-R-114).

**References**

1. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995.
2. Tavtigian SV, Simard J, Rommens J, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12: 333-337, 1996.
3. Jakubowska A, Nej K, Huzarski T, Scott RJ and Lubinski J: BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 87: 888-891, 2002.
4. Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182, 2002.
5. Liede A, Karlan BY and Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22: 735-743, 2004.
6. Patel KJ, Yu VP, Lee H, et al: Involvement of BRCA2 in DNA repair. Mol Cell 1: 347-357, 1998.
7. Moynahan ME, Pierce AJ and Jasin M: BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7: 263-272, 2001.

8. O’Donovan PJ and Livingston DM: BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31: 961-967, 2010.

9. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005.

10. Wang W and Figg WD: Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol Ther 7: 1004-1005, 2008.

11. Thompson LH and Schild D: Homologous recombination repair of DNA ensures mammalian chromosome stability. Mutat Res 477: 153-171, 2001.

12. Pellegrini L and Venkitaraman A: Emerging functions of BRCA2 in DNA recombination. Trends Biochem Sci 29: 310-316, 2004.

13. Shivi JK and Venkitaraman AR: DNA recombination, chromosomal stability and carcinogenesis: insights into the role of BRCA2. DNA Repair (Amst) 3: 835-843, 2004.

14. Ohnishi T, Mori E and Takahashi A: DNA double-strand breaks: their production, recognition, and repair in eukaryotes. Mutat Res 669: 8-12, 2009.

15. Davies AA, Masson JY, McLlwraith MJ, et al: Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7: 273-282, 2001.

16. Foster ER and Downs JA: Histone H2A phosphorylation in DNA double-strand break repair. FEBS J 272: 3231-3240, 2005.

17. Esashi F, Galkin VE, Yu X, et al: Stabilization of RAD51 nucleo-protein filaments by the C-terminal region of BRCA2. Nat Struct Mol Biol 14: 468-474, 2007.

18. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998.

19. van Attikum H, Fritsch O, Hohn B and Gasser SM: Recruitment of a new method for the determination of nitrosamines by micellar electrokinetic capillary chromatography. Water Res 37: 3837-3842, 2003.

20. Brambilla G and Martelli A: Genotoxic and carcinogenic risk to humans of drug-nitrite interaction products. Mutat Res 635: 17-52, 2007.

21. Hecht SS: Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis. Proc Soc Exp Biol Med 216: 181-191, 1997.

22. Williams GM, Iatropoulos MJ, Jeffrey AM, Luo FQ, Wang CX and Pittman B: Diethylnitrosamine exposure-responses for DNA ethylation, hepatocellular proliferation, and initiation of carcinogenesis in rat liver display non-linearities and thresholds. Arch Toxicol 73: 394-402, 1999.

23. Pinto LF, Moraes E, Albano R, et al: Rat oesophageal cytochrome P450 (CYP) monoxygenase system: comparison to the liver and relevance in N-nitrosodimethylamine carcinogenesis. Carcinogenesis 22: 1877-1883, 2001.

24. Visoni S, Lang M and Ribeiro Pinto LF: Hamster exhibits major differences in organ-specific metabolism of the esophageal carcinogen N-nitrosodimethylamine. Toxicol Lett 183: 90-94, 2008.

25. International Agency for Research on Cancer (IARC): Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl 7: 1-440, 1987.

26. International Agency for Research on Cancer (IARC): Some N-Nitroso Compounds. IARC Monogr Eval Carcinog Risks Hum 17: 1-365, 1978.

27. International Agency for Research on Cancer (IARC): Tobacco habits other than smoking; betel-quid and areca-nut chewing; and some related nitrosamines. IARC Working Group. Lyon, 23-30 October 1984. IARC Monogr Eval Carcinog Risk Chem Hum 37: 1-268, 1985.

28. Bradley MO, Dysart G, Fitzsimmons K, Harbach P, Lewin J and Wolf G: Measurements by filter elution of DNA single- and double-strand breaks in rat hepatocytes: effects of nitrosamines and gamma-irradiation. Cancer Res 42: 2592-2597, 1982.

29. Loeppky RN, Ye Q, Goelzer P and Chen Y: DNA adducts from N-nitrosodiethanolamine and related beta-oxidized nitrosamines in vivo: (32)P-postlabeling methods for glyoxal- and O(6)-hydroxyethyldeoxyguanosine adducts. Chem Res Toxicol 15: 470-482, 2002.

30. Wiltshire T, Sentf J, Wang Y, et al: BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Mol Pharmacol 71: 1051-1060, 2007.

31. Wang Y, Wiltshire T, Sentf J, et al: Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Mol Cancer Ther 5: 3153-3161, 2006.

32. Fillingham J, Keogh MC and Krogan NJ: GammaH2AX and its role in DNA double-strand break repair. Biochem Cell Biol 84: 568-577, 2006.

33. Dickey JS, Redon CE, Nakamura AJ, et al: H2AX: functional roles and potential applications. Chromosoma 118: 683-692, 2009.

34. Phillips ER and McKinnon PJ: DNA double-strand break repair and development. Oncogene 26: 7799-7808, 2007.

35. Hefferin ML and Tomkinson AE: Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst) 4: 639-648, 2005.

36. Schoenfeld AR, Aggar S, Dolios G, Wang R and Aaronson SA: BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cell cycle. Mol Cell 24: 7444-7455, 2004.

37. Philip S, Swaminathan S, Kuznetsov SG, et al: Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications. Cancer Res 68: 9973-9981, 2008.